MichaelJamesDowningMD

Psychiatry • Dallas, TX

Physician

Join to view full profile

Are you Dr. Downing?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 66 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
12404 Park Central Dr Ste 220s
Dallas, TX 75251
Phone+1 214-868-2345

Fax+1 214-369-2610

Summary

Dr. Michael Downing, MD is a board certified psychiatrist in Dallas, Texas. He is currently licensed to practice medicine in Texas. He is affiliated with Texas Health Presbyterian Hospital Dallas.

Education & Training

University of Texas Southwestern Medical CenterResidency, Psychiatry, 1990 - 1994
McGovern Medical School at UTHealthClass of 1990

Certifications & Licensure

TX State Medical License 1992 - 2026
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose Start of enrollment: 2011 Sep 01
Completed
Phase 3
Major Depressive Disorder With Mixed Features - Extension Start of enrollment: 2011 Sep 01
Completed
Phase 3
PEARL Schizophrenia Maintenance Start of enrollment: 2011 Sep 01
Completed
Phase 3
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Start of enrollment: 2013 Oct 01
Completed
Phase 2
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Start of enrollment: 2013 Nov 01
Completed
Phase 3
12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
Completed
Phase 3
PRC-063 in Adolescent ADHD Start of enrollment: 2014 Apr 01
Completed
Phase 3
Open-label Safety Study in Adults With ADHD Start of enrollment: 2014 Jun 01
Completed
Phase 3
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD Start of enrollment: 2014 May 01
Completed
Phase 3
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Completed
Phase 3
This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia Start of enrollment: 2019 Apr 15
Completed
Phase 2
Join now to see all